Scientific Foundation
Biomolecular LLC's nEMS therapy is built on decades of peer-reviewed research in electrophysiology, bioelectronic medicine, and artificial intelligence — bridging classical bioelectric science with cutting-edge therapeutic innovation.
Type 2 Diabetes Mellitus Treatment: The Therapeutic Gap
Type 2 Diabetes Mellitus (T2DM) remains one of the most significant public health challenges of the twenty-first century. About 500 million people worldwide are affected by the disease, and its prevalence continues to increase because of aging populations, sedentary lifestyles, obesity, and metabolic disorders (Huang et al., 2025; Khan et al., 2020). T2DM is a major cause of cardiovascular disease, chronic kidney disease, peripheral neuropathy, retinopathy, lower-limb amputations, and premature mortality.
Despite substantial advances in pharmacological management, current therapies remain largely palliative rather than correcting the underlying physiological abnormalities responsible for disease progression. Most therapeutic interventions target lowering blood glucose levels through exogenous insulin administration, increased cellular insulin sensitivity, or altered glucose metabolism. However, many patients continue to experience progressive pancreatic β-cell dysfunction, increasing insulin resistance, and eventual development of irreversible diabetes complications.
This therapeutic gap is a critical unmet need warranting innovative approaches capable of restoring endogenous metabolic regulation and addressing the neurophysiological dysfunctions underlying T2DM progression.
Inspired by this unmet therapeutic need in diabetes care, Biomolecular LLC is actively seeking to develop innovative, non-invasive bioelectronic therapies capable of restoring physiological function rather than merely conferring palliative benefits.
Bioelectronic Therapy in T2DM: What's the Scientific Foundation?
The scientific foundation underpinning Biomolecular LLC's research endeavors in diabetes therapeutics is based on the premise that T2DM is not solely a metabolic-endocrine disorder but also a disease involving significant neurophysiological dysregulation within the brain-pancreas neural axis (Ahrițculesei et al., 2025; Liang et al., 2025).
"Neuroimaging studies reveal early imbalances in excitatory and inhibitory neurotransmitters, while biochemical and histological findings demonstrate altered receptor expression in both the brain and pancreatic islets."
— Ahrițculesei et al. (2025)
Pancreatic β-cell dysfunction represents one of the principal pathophysiological hallmarks of uncontrolled T2DM. The neurophysiological connection is that proper β-cell activity depends on maintenance of membrane potential integrity and voltage-dependent calcium ion (Ca²⁺) signaling pathways within the brain-pancreas neural axis (Rorsman & Ashcroft, 2018).
Calcium signaling is essential for:
- Insulin secretion
- Cellular metabolism
- Gene transcription
- β-cell survival and regeneration
- Neuroendocrine communication
Progressive impairment of membrane depolarization and calcium channel function contributes directly to decreased insulin production and worsening metabolic dysregulation (Jacobson & Shyng, 2020). The vagus or parasympathetic nerve (originating from dorsal motor vagal nuclei), the spinal or sympathetic nerve (originating from celiac and mesenteric ganglia), and sensory fibers (originating from dorsal root ganglia) innervate the pancreatic islets (Lin et al., 2021; Lkhagvasuren et al., 2021).
Increasing evidence suggests that chronic activation of the sympathetic nervous system (SNS) contributes significantly to:
- Insulin resistance
- Hepatic glucose overproduction
- Chronic inflammation
- Dysregulated energy metabolism
- Progressive deterioration of glucose homeostasis
The central hypothesis underlying our therapeutic frontier is that targeted neurophysiologic modulation of the right ganglia structures may restore dysfunctional calcium signaling pathways in the pancreatic islets and the brain, improving endogenous metabolic regulation.
The novel metabolic treatment method is a secondary discovery from Vestibular Science, originally described in the Nobel Prize-winning work by Robert Barany (Lopez & Blanke, 2014). Dr. Carabeo proposed a transformative idea to Julio L. Garcia, M.D., that the abnormal bioelectric signals, a diagnostic indicator of vestibular dysfunction, could be harnessed for treatment. The asymmetric biphasic waveform tailored to counter the defective bioelectric signal was proposed, forming the cornerstone of the novel neurophysiologic electromagnetic stimulation.
Patented Neurophysiologic Electromagnetic Stimulation (nEMS) Technology
Biomolecular LLC has been at the forefront of translating frontier research into therapeutic solutions for T2DM through its two patented inventions (Garcia et al., 2012; Julio Luis Garcia et al., 2014).
Method, System and Apparatus for Control of Pancreatic Beta Cell Function to Improve Glucose Homeostasis and Insulin Production
Device for Neuro-Physiologic Stimulation
These patented technologies culminated in a novel, non-invasive Neurophysiologic Electromagnetic Stimulation (nEMS) therapy specifically for treating T2DM.
The patented device has the therapeutic potential to restore, at least functionally, the dysregulated membrane potentials within pancreatic β-cells. Voltage-dependent calcium signaling mechanisms within the pancreatic islet of Langerhans are responsible for endogenous insulin secretion and glucose regulation.
Unlike conventional therapies that replace insulin or pharmacologically alter glucose metabolism, the patented nEMS approach aims to restore the body's own neurophysiological poise and regulatory mechanisms.
The primary therapeutic objectives of the patented nEMS device are:
- 1.Restoration of the membrane potential of pancreatic β-cells.
- 2.Reactivation of voltage-dependent calcium ion channels in the pancreatic β-cells.
- 3.Restore the islet of Langerhans' efficiency in endogenous insulin production.
- 4.Reduction of autonomic dysregulation.
- 5.Functional restoration of glucose metabolism and homeostasis.
The long-term vision of this technology is to provide a non-invasive therapeutic alternative that may reduce dependence on lifelong diabetes pharmacotherapy.
The Innovative Advanced Reverberatory Neural Circuit
One of the distinguishing features of the patented technology is the incorporation of an Advanced Reverberatory Neural Circuit (AdRNC) principle.
Classical neurophysiology describes reverberatory circuits as neural pathways capable of continuous self-reactivation after an initiating stimulus. Such circuits can maintain physiological responses long after the original stimulus has ended.
The patented AdRNC technology seeks to emulate these biological mechanisms through engineered electromagnetic stimulation patterns that may induce sustained neurophysiological effects.
Replication of reverberatory neural mechanisms may enable prolonged therapeutic responses and functional restoration of autonomic signaling pathways involved in glucose regulation (Garcia et al., 2012; Julio Luis Garcia et al., 2014).
This concept represents a significant departure from conventional stimulation technologies that generally produce only transient physiological effects.
The Innovative Neurophysiologic Bi-Waveform Technology
A second innovative feature of the patented platform is the neurophysiologic bi-waveform, a pulse invention specifically designed to modulate sympathetic nervous system (SNS) activity.
The sympathetic nervous system regulates numerous metabolic functions, including:
- Glucose production
- Pancreatic endocrine function
- Energy expenditure
- Cardiovascular regulation
- Stress-response pathways
Chronic sympathetic hyperstimulation has been associated with insulin resistance, obesity, systemic inflammation, and progression of T2DM.
The targeted bi-waveform pulse on the SNS normalizes dysregulated autonomic signaling and sustains physiological insulin secretion. By restoring autonomic balance, the technology may offer a novel mechanism for improving glucose metabolism and preventing disease progression.
The therapeutic waveform is delivered in a precise cycle: six seconds of active stimulation targeting specific neural pathways followed by a two-second rest period. The 'active' and 'rest' cycle creates a reverberatory circuit of the nervous system, sustaining neural activity in the brain-pancreas neural axis. This stimulates the pancreatic endocrine system (incretin effect), which powerfully elicits insulin release from pancreatic beta cells (Drucker & Nauck, 2006).
The Patented Neuro-Physiologic Stimulation Device Applicator
The patented device (U.S. Patent No. 8,688,240) incorporates a proprietary asymmetric biphasic waveform consisting of two therapeutic phases. The initial positive phase delivers a brief (approx. 50 milliseconds), high-energy pulse that targets autonomic neural pathways involved in pancreatic-endocrine regulation. This is followed by a prolonged negative phase (approx. 206 milliseconds), which is designed to sustain ion channel activation and potentially enhance calcium ion (Ca²⁺) influx, a critical component of insulin secretion and β-cell function.
Together, the patented applicator and waveform represent a novel bioelectronic approach aimed at restoring endogenous metabolic regulation through non-invasive neurophysiologic modulation.
nEMS Technology in Action
Watch how Biomolecular LLC's patented neurophysiologic electromagnetic stimulation technology works to address the root causes of Type 2 Diabetes Mellitus through targeted neural pathway modulation.
A Multi-Phase, Bilateral nEMS Treatment Protocol
The nEMS treatment protocol entails modulating specific autonomic neural pathways in the brain-pancreas neural axis. This multiphase treatment protocol targets bidirectional communication between the central nervous system, autonomic ganglia, and pancreatic islets, which play a critical role in maintaining glucose homeostasis and energy metabolism (Lkhagvasuren et al., 2021). The protocol involves four phases to achieve nEMS therapy efficiency.
Parasympathetic (Vagal) Neuromodulation
The initial phase targets pathways associated with the vagus nerve, the principal parasympathetic pathway connecting the brain and pancreas. The secretion of pancreatic juice in response to stimulation of the vagus nerves was originally demonstrated in animal studies on pigs and dogs (Hickson, 1970). Up-to-date evidence supports that vagal efferent signaling promotes pancreatic β-cell activity, enhances glucose-stimulated insulin secretion, and establishes a feedback loop that coordinates islet responses during carbohydrate ingestion. This phase aims to restore the physiological poise of the parasympathetic nerve, thereby potentially improving dysregulated neuroendocrine signaling in individuals with T2DM.
Sympathetic and Celiac Plexus Neuromodulation
The second phase targets the celiac and superior mesenteric ganglia, which are the major sympathetic pathways innervating the pancreas. The literature on the brain-pancreas axis suggests that sympathetic activation influences insulin and glucagon secretion, hepatic glucose output, and overall energy balance poise (Lkhagvasuren et al., 2021). Targeting these autonomic ganglia for nEMS neuromodulation may functionally restore dysregulated sympathetic activity that underlies insulin resistance, chronic hyperglycemia, and diabetic neuropathy.
Sacral and Spinal Autonomic Integration
The third neuromodulation phase addresses lower spinal autonomic pathways, particularly sacral pathways that contribute to neuroendocrine integration. Although pancreatic innervation is primarily mediated by thoracic sympathetic and vagal pathways, sacral modulation may influence broader autonomic homeostasis and neuroendocrine integration, both of which are pivotal to metabolic dysfunction in T2DM. This phase aims to restore the reverberatory neural signaling pathway and enhance overall stability and poise of the autonomic pathway.
Bilateral Neuromodulation and Neural Network Synchronization
Given the bilateral organization of autonomic innervation and central neural processing, the complete treatment sequence is subsequently repeated contralaterally. Bilateral application or "spinal axial reversal" guarantees that the entire neural network innervating the pancreas is thoroughly engaged. This minimizes asymmetrical autonomic activity and promotes coordinated signaling throughout the brain-pancreas axis.
Anatomical Mapping: Solving Electrode-Placement Optimization
The autonomic innervation of pancreatic tissues provides a strong anatomical rationale for therapeutic neurostimulation.
The sympathetic network supplying the pancreatic islets and liver originates primarily through the splanchnic nerves and associated ganglionic structures, including:
- Paravertebral ganglia
- Superior mesenteric ganglia
- Celiac plexus pathways
- Vagal afferent nerve networks
These neural structures, which reside within the brain-pancreas neural axis, represent potentially effective targets for therapeutic neuromodulation. However, considering different physiques and BMI status, there could be substantial anatomical and neurophysiological variability among individuals with diabetes regarding ganglionic positioning, neural branching patterns, tissue conductivity to electromagnetic signal, and physiological responsiveness to neurostimulation.
Consequently, precise identification of optimal stimulation sites remains one of the principal challenges facing the advancement of neurostimulation therapies for T2DM. This can be solved through machine learning integration with nEMS.
Artificial Intelligence Integration
Biomolecular LLC is addressing this precision challenge through Machine Learning (ML) integration into the patented nEMS system.
Recent advances in ML, computational neuroscience, and precision medicine provide unprecedented opportunities to personalize therapeutic interventions.
AI methodologies may enable:
- Patient-specific electrode mapping
- Identification of optimal ganglionic targets
- Digital reconstruction of autonomic anatomy
- Prediction of therapeutic responses
- Adaptive optimization of stimulation parameters
- Continuous therapeutic learning and refinement
Potential computational approaches for this integration include:
- Deep Neural Networks
- Recurrent Neural Networks
- Reinforcement Learning Algorithms
- Finite Element Analysis
- Multiphysics Modeling
The integration of AI with nEMS technologies has the potential to transform neurostimulation from a generalized intervention into a precision bioelectronic therapy for T2DM.
Preliminary Scientific Evidence
of experts endorsed AI's ability to predict optimal neurostimulation sites in nEMS therapy
Data adapted from U.S. Patent No. 8,457,745 – Garcia et al. (2012)
Preclinical research led by the Principal Investigator, Dr. Oresteban Carabeo, PhD, demonstrated durable therapeutic effects in patients with T2DM following nEMS therapy. Three ethnic groups discontinued insulin therapy within five months of the nEMS therapy trial, with therapeutic durability lasting up to at least one year (Garcia et al., 2012).
Dr. Carabeo also conducted preliminary investigations exploring the feasibility and potential significance of AI-enabled neurostimulation approaches (Carabeo, 2025).
Expert surveys and interviews involving clinicians, diabetes specialists, artificial intelligence experts, and biomedical professionals demonstrated substantial support for the proposed AI-nEMS integration. Quantitative findings strongly supported AI-guided electrode placement, with 76% of the respondents endorsing AI's ability to predict optimal neurostimulation sites in nEMS therapy.
These findings support continued development of AI-guided peripheral neurostimulation therapies for T2DM.
Future Development and Commercialization Strategy
The long-term objective of Biomolecular LLC is to establish a new paradigm in chronic disease management through intelligent precision neuromodulation.
Phase I
- AI algorithm development
- Computational anatomical mapping
Phase II
- Integration of adaptive machine learning systems
- Validation of personalized stimulation protocols
- Preclinical evaluation and translational studies
Future Clinical Development
- Human feasibility studies
- Clinical validation
- Regulatory development
- Commercialization activities
Beyond T2DM, the underlying platform technologies may have applications in the management of:
Biomolecular LLC envisions a future in which medicine moves beyond symptom management toward restoration of physiological function through intelligent bioelectronic systems. The convergence of artificial intelligence, neurophysiology, computational mapping methods, and biomedical engineering provides an unprecedented opportunity to transform the treatment of chronic diseases, in general. Our mission is to develop adaptive, personalized, and non-invasive therapeutic technologies capable of restoring endogenous neurophysiological poise and improving patient outcomes worldwide.
Partner with usAhrițculesei, R.-V., et al. (2025). Neurotransmitter alterations in prediabetes and type 2 diabetes mellitus. International Journal of Molecular Sciences, 26(16), 7847.
Carabeo, O. (2025). Integration of AI, innovative neurophysiologic electromagnetic stimulation, and reverberatory circuitry in diabetes treatment. Capitol Technology University.
Drucker, D. J., & Nauck, M. A. (2006). The incretin system. Lancet, 368(9548), 1696–1705.
Garcia, J. L., Carabeo, O., Valdes, R., & Valdes, R. (2012). U.S. Patent No. 8,457,745. U.S. Patent and Trademark Office.
Garcia, J. L., Carabeo, O., Valdes, R., & Valdes, R. (2014). U.S. Patent No. 8,768,468. U.S. Patent and Trademark Office.
Huang, X., et al. (2025). Global burden of type 2 diabetes mellitus caused by high BMI. Frontiers in Public Health, 13.
Jacobson, D. A., & Shyng, S. L. (2020). Ion channels of the islets in type 2 diabetes. Journal of Molecular Biology, 432(5), 1326–1346.
Khan, M. A. B., et al. (2020). Epidemiology of type 2 diabetes. Journal of Epidemiology and Global Health, 10(1), 107–111.
Kyrou, I., Randeva, H. S., & Tsigos, C. (2017). Stress, insulin resistance, and type 2 diabetes. In Stress: Neuroendocrinology and neurobiology (pp. 351–358). Academic Press.
Liang, Y., et al. (2025). Altered static and dynamic intrinsic brain activity patterns in type 2 diabetic patients. Scientific Reports, 16(1), 1142.
Lin, E. E., Scott-Solomon, E., & Kuruvilla, R. (2021). Peripheral innervation in the regulation of glucose homeostasis. Trends in Neurosciences, 44(3), 189–202.
Lkhagvasuren, B., et al. (2021). Pancreas-brain crosstalk. Frontiers in Neuroanatomy, 15, 691777.
Lopez, C., & Blanke, O. (2014). Nobel prize centenary: Robert Bárány and the vestibular system. Current Biology, 24(21), R1026–1028.
Rorsman, P., & Ashcroft, F. M. (2018). Pancreatic β-cell electrical activity and insulin secretion. Physiological Reviews, 98(1), 117–214.